Liver diseases therapeutics market expected to reach USD 10.9 billion by 2018

According a market report published by Transparency Market Research, U.S.-based market intelligence firm, the worldwide market for liver diseases therapeutics was estimated to be worth USD 6.5 billion in 2011, and will reach USD 10.9 billion in 2018, at a CAGR of 8.6% between 2012 and 2018. The report, “Liver Diseases Therapeutics Market - Global Industry Analysis, Size, Share, Trends And Forecast 2012 - 2018” states that among the entire drug class as covered in the report, anti-viral drugs  are expected to lead the industry by 2018 as far as revenue generation is concerned. The anti-viral segment will account for 32.7% of the total market share, followed by vaccines with 19.1% in 2018.
 
Get Samplet Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=799

The major growth drivers of the global liver diseases therapeutics market highlighted in the TMR report are widespread prevalence of liver diseases, rising geriatric population, a high level of unmet requirements in liver cancer and rise in vaccination in emerging nations. The report also identifies some opportunities that may prove beneficial to the market in future. These include emerging markets in developing countries such as those in Asia, Eastern Europe and Latin America, a number of strong and highly-effective drugs in the pipeline and integrated opportunities in the overall healthcare industry. However, the study also throws light on those factors that risk the growth of the market. The side-effects and risks of the drugs, stringent FDA approvals and government regulations, and the availability of substitute intervention procedures are some of the restraints of the worldwide liver diseases therapeutics market.
 
Browse the full Liver Diseases Therapeutics Market (Chemotherapy, Anti-Virals, Vaccines, Targeted Therapy and Immunosuppressants) - Global Industry Analysis, Size, Share, Trends And Forecast 2012 - 2018 report at http://www.transparencymarketresearch.com/liver-diseases-therapeutics.html
 
The five main types of liver diseases and therapy options as mentioned in the report are autoimmune liver disorder, non-alcoholic fatty liver disease, alcohol induced liver disease, hepatocellular carcinoma, and viral/hepatitis liver disorder. The report segments the liver diseases therapeutics industry on the basis of drug class into:

• Chemotherapy drugs
• Immunosuppressants
• Vaccines
• Targeted therapy drugs
• Anti-viral drugs
• Corticosteroids
• Immunoglobulins

On the basis of region, the market is segmented into North America, Europe, Asia-Pacific and Rest of the World.
 
The report has an extensive section on the competitive landscape of the market and some of the companies profiled in the study are Novartis, Pfizer, Astellas Pharma Inc., Abbot Laboratories, Merck & Co., Gilead Science Inc., Roche, and Bristol-Myers Squibb. 

About Us: 
Transparency Market Research (TMR) is a U.S. based provider of syndicated research, customized research, and consulting services. TMR’s global and regional market intelligence coverage includes industries such as pharmaceutical, chemicals and materials, technology and media, food and beverages, and consumer goods, among others. Each TMR research report provides clients with a 360-degree view of the market with statistical forecasts, competitive landscape, detailed segmentation, key trends, and strategic recommendations.

Contact:

Mr. Nachiket Ghumare
90 State Street, Suite 700
Albany, NY 12207
United States.
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com
Blog: http://www.tmrblog.com/